Javier Maynar

1.6k total citations
33 papers, 1.0k citations indexed

About

Javier Maynar is a scholar working on Pharmacology, Molecular Medicine and Infectious Diseases. According to data from OpenAlex, Javier Maynar has authored 33 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Pharmacology, 8 papers in Molecular Medicine and 7 papers in Infectious Diseases. Recurrent topics in Javier Maynar's work include Antibiotics Pharmacokinetics and Efficacy (17 papers), Antibiotic Resistance in Bacteria (8 papers) and Hemodynamic Monitoring and Therapy (6 papers). Javier Maynar is often cited by papers focused on Antibiotics Pharmacokinetics and Efficacy (17 papers), Antibiotic Resistance in Bacteria (8 papers) and Hemodynamic Monitoring and Therapy (6 papers). Javier Maynar collaborates with scholars based in Spain, France and United Kingdom. Javier Maynar's co-authors include Arantxa Isla, Alicia Rodríguez‐Gascón, José Luís Pedraz, José Ángel Sánchez‐Izquierdo, Helena Barrasa, A. Herrero San Martín, Esther Corral, Maria Ángelés Solinís, Jordi Rello and Marcos Maynar-Mariño and has published in prestigious journals such as Journal of Chromatography A, Journal of Antimicrobial Chemotherapy and Critical Care.

In The Last Decade

Javier Maynar

33 papers receiving 1.0k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Javier Maynar Spain	21	499	267	207	176	158	33	1.0k
Bernard Georges France	19	359 0.7×	224 0.8×	124 0.6×	176 1.0×	146 0.9×	49	1.0k
Jean‐Marie Conil France	19	470 0.9×	338 1.3×	113 0.5×	254 1.4×	156 1.0×	67	1.2k
Mojtaba Mojtahedzadeh Iran	23	322 0.6×	485 1.8×	136 0.7×	165 0.9×	145 0.9×	166	1.8k
Claire Dahyot‐Fizelier France	21	479 1.0×	469 1.8×	132 0.6×	207 1.2×	96 0.6×	56	1.6k
Salvatore Lucio Cutuli Italy	20	167 0.3×	303 1.1×	202 1.0×	164 0.9×	85 0.5×	81	1.2k
Hendrik Bracht Germany	21	677 1.4×	697 2.6×	226 1.1×	231 1.3×	203 1.3×	75	1.9k
João Pedro Baptista Portugal	12	503 1.0×	321 1.2×	173 0.8×	83 0.5×	266 1.7×	36	826
Luca Montini Italy	22	299 0.6×	366 1.4×	162 0.8×	364 2.1×	87 0.6×	44	1.9k
Melissa Lassig‐Smith Australia	14	446 0.9×	230 0.9×	87 0.4×	169 1.0×	147 0.9×	26	704
Michael Zöller Germany	24	714 1.4×	548 2.1×	309 1.5×	256 1.5×	68 0.4×	84	1.4k

Countries citing papers authored by Javier Maynar

Since Specialization

Citations

This map shows the geographic impact of Javier Maynar's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Javier Maynar with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Javier Maynar more than expected).

Fields of papers citing papers by Javier Maynar

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Javier Maynar. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Javier Maynar. The network helps show where Javier Maynar may publish in the future.

Co-authorship network of co-authors of Javier Maynar

This figure shows the co-authorship network connecting the top 25 collaborators of Javier Maynar. A scholar is included among the top collaborators of Javier Maynar based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Javier Maynar. Javier Maynar is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Barrasa, Helena, Javier Maynar, Andrés Canut-Blasco, et al.. (2023). Ceftaroline and Avibactam Removal by Continuous Renal Replacement Therapies: An in vitro Study. Blood Purification. 52(5). 464–473. 2 indexed citations

Barrasa, Helena, Alicia Rodríguez‐Gascón, Eduardo Asín‐Prieto, et al.. (2022). Optimization of levetiracetam dosing regimen in critically ill patients with augmented renal clearance: a Monte Carlo simulation study. Journal of Intensive Care. 10(1). 21–21. 9 indexed citations

Barrasa, Helena, A. Herrero San Martín, Javier Maynar, et al.. (2020). High rate of infections during ICU admission of patients with severe SARS-CoV-2 pneumonia: A matter of time?. Journal of Infection. 82(5). 186–230. 14 indexed citations

Barrasa, Helena, A. Herrero San Martín, José Ángel Sánchez‐Izquierdo, et al.. (2020). Impact of augmented renal clearance on the pharmacokinetics of linezolid: Advantages of continuous infusion from a pharmacokinetic/pharmacodynamic perspective. International Journal of Infectious Diseases. 93. 329–338. 36 indexed citations

Neri, Mauro, Anna Lorenzin, Massimo de Cal, et al.. (2019). ACUsmart Continuous Renal Replacement Therapy Platform: Multicenter Pilot Study for Technical and Clinical Assessment (A.M.P. Study). Blood Purification. 48(1). 60–66. 2 indexed citations

Asín‐Prieto, Eduardo, Alicia Rodríguez‐Gascón, Helena Barrasa, et al.. (2018). Population pharmacokinetics of daptomycin in critically ill patients. International Journal of Antimicrobial Agents. 52(2). 158–165. 34 indexed citations

Barrasa, Helena, Arantxa Isla, A. Herrero San Martín, et al.. (2018). Pharmacokinetics of linezolid in critically ill patients on continuous renal replacement therapy: Influence of residual renal function on PK/PD target attainment. Journal of Critical Care. 50. 69–76. 26 indexed citations

Ochagavía, A., F. Baigorri, Jaume Mesquida, et al.. (2013). Monitorización hemodinámica en el paciente crítico. Recomendaciones del Grupo de Trabajo de Cuidados Intensivos Cardiológicos y RCP de la Sociedad Española de Medicina Intensiva, Crítica y Unidades Coronarias. Medicina Intensiva. 38(3). 154–169. 39 indexed citations

Asín‐Prieto, Eduardo, Alicia Rodríguez‐Gascón, Iñaki F. Trocóniz, et al.. (2013). Population pharmacokinetics of piperacillin and tazobactam in critically ill patients undergoing continuous renal replacement therapy: application to pharmacokinetic/pharmacodynamic analysis. Journal of Antimicrobial Chemotherapy. 69(1). 180–189. 58 indexed citations

10.

Maynar, Javier, Fernando Martínez‐Sagasti, M.E. Herrera-Gutiérrez, et al.. (2013). Direct hemoperfusion with polymyxin B-immobilized cartridge in severe sepsis due to intestinal perforation: hemodynamic findings and clinical considerations in anticoagulation therapy.. PubMed. 26(2). 151–8. 7 indexed citations

11.

Sabatier, C., et al.. (2011). Valoración de la precarga y la respuesta cardiovascular al aporte de volumen. Medicina Intensiva. 36(1). 45–55. 20 indexed citations

12.

Isla, Arantxa, et al.. (2006). Elimination of Piperacillin and Tazobactam by Renal Replacement Therapies with AN69 and Polysulfone Hemofilters: Evaluation of the Sieving Coefficient. Blood Purification. 24(4). 347–354. 23 indexed citations

13.

Maynar, Javier, Alicia Rodríguez‐Gascón, Arantxa Isla, et al.. (2005). Influence of Renal Function on the Pharmacokinetics of Piperacillin/Tazobactam in Intensive Care Unit Patients During Continuous Venovenous Hemofiltration. The Journal of Clinical Pharmacology. 45(2). 168–176. 59 indexed citations

14.

Isla, Arantxa, et al.. (2005). Determination of ceftazidime and cefepime in plasma and dialysate-ultrafiltrate from patients undergoing continuous veno-venous hemodiafiltration by HPLC. Journal of Pharmaceutical and Biomedical Analysis. 39(5). 996–1005. 34 indexed citations

15.

Isla, Arantxa, Javier Maynar, José Ángel Sánchez‐Izquierdo, et al.. (2005). Meropenem and Continuous Renal Replacement Therapy: In Vitro Permeability of 2 Continuous Renal Replacement Therapy Membranes and Influence of Patient Renal Function on the Pharmacokinetics in Critically Ill Patients. The Journal of Clinical Pharmacology. 45(11). 1294–1304. 47 indexed citations

16.

Isla, Arantxa, et al.. (2005). Cefepime and continuous renal replacement therapy (CRRT): In vitro permeability of two CRRT membranes and pharmacokinetics in four critically ill patients. Clinical Therapeutics. 27(5). 599–608. 49 indexed citations

17.

Isla, Arantxa, et al.. (2005). Quantitation and stability of piperacillin and tazobactam in plasma and ultrafiltrate from patients undergoing continuous venovenous hemofiltration by HPLC. Biomedical Chromatography. 19(8). 570–578. 23 indexed citations

18.

Kindgen‐Milles, Detlef, Didier Journois, Roberto Fumagalli, et al.. (2005). Study protocol: The DOse REsponse Multicentre International collaborative initiative (DO-RE-MI). Critical Care. 9(4). R396–406. 9 indexed citations

19.

Navajas, Rosana, et al.. (1993). Determination of ephedrines in urine by high-performance liquid chromatography. Journal of Chromatography A. 631(1-2). 201–205. 30 indexed citations

20.

Maynar-Mariño, Marcos, et al.. (1991). Erythrocyte Free Radical Scavenger Enzymes in Bicycle Professional Racers. Adaptation to Training. International Journal of Sports Medicine. 12(6). 563–566. 113 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact